PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?
According to the current published data, using PCSK9i to prevent MACE seems to be a very expensive strategy. If upcoming outcome trials will demonstrate similar results, it seems that at current prices, using these drugs would not be affordable for most healthcare systems.
These findings suggest that microRNA changes observed in Huntington's disease brain may be detectable in plasma and have potential clinical utility.